Skip to main content
. Author manuscript; available in PMC: 2007 Sep 17.
Published in final edited form as: Pharmacogenet Genomics. 2006 Dec;16(12):891–899. doi: 10.1097/01.fpc.0000236324.96056.16

Table 7.

NOS3 haplotype by smoking interaction and risk of incident CHD and stroke in Caucasiansa,b

Smoking exposure Haplotype Interactionc
CHDd Non-CT n = 430/350 CT n = 305/256
Current smoker
 No 1 (referent) 1.00 (0.74−1.35) 1.50 (0.83−2.70)
 Yes 1.46 (1.00−2.13) 2.18 (1.40−3.38) P=0.179
Pack-years
 < 20 years 1 (referent) 0.95 (0.68−1.33) 1.39 (0.84−2.30)
 ≥ 20 years 1.32 (0.93−1.87) 1.74 (1.21−2.51) P=0.206
Strokee Non-CT n = 84/374 CT n = 58/276
Current smoker
 No 1 (referent) 0.87 (0.53−1.45) 1.59 (0.65−3.86)
 Yes 1.67 (0.92−3.04) 2.32 (1.18−4.51) P=0.309
Pack-years
 < 20 years 1 (referent) 0.92 (0.52−1.63) 1.24 (0.54−2.80)
 ≥ 20 years 1.70 (0.98−2.94) 1.93 (0.99−3.74) P=0.610

CHD, coronary heart disease; HRR, hazard rate ratio; CI, confidence interval.

a

Number of cases/noncases in each haplotype cell.

b

Data presented as HRR (95% CI).

c

Multiplicative haplotype by smoking interaction term HRR (95% CI), and P-value.

d

Adjusted for age, sex, study center, diabetes, hypertension, HDL cholesterol, total cholesterol, and body mass index.

e

Adjusted for age, sex, study center, diabetes, and hypertension.